MarketCap
Facebook
X
Telegram
Nemaura Medical EBITDA | NMRD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Nemaura Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.15 M | -7.34 M | -4.49 M | -4.72 M | -4.44 M | -904 K | -456 K | -358 K | -321 K | -581 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -321 K | -9.15 M | -3.28 M |
Quarterly EBITDA Nemaura Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.23 M | -1.82 M | -1.74 M | - | -365 K | -2.07 M | -2.34 M | -1.62 M | -1.65 M | -2.34 M | - | -1.79 M | -1 M | -3.25 M | -1.58 M | -1.07 M | -1.01 M | -1.09 M | -1.24 M | -1.06 M | -911 K | -1.14 M | -765 K | -933 K | -454 K | -432 K | -412 K | -476 K | -360 K | -311 K | -489 K | -375 K | -316 K | -381 K | -399 K | -329 K | -153 K | -354 K | -403 K | -159 K | -268 K | -623 K | - | -340 K | -422 K | -82.8 K | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -82.8 K | -3.25 M | -920 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Butterfly Network
BFLY
|
-79.7 M | $ 6.5 | -2.1 % | $ 1.61 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 8.45 | -1.97 % | $ 616 M |  Israel |
 |
Beyond Air
XAIR
|
-25.9 M | $ 2.52 | 10.34 % | $ 20.9 B | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 6.99 | -5.35 % | $ 1.05 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Bio-Rad Laboratories
BIO
|
213 M | $ 388.54 | 0.06 % | $ 10.6 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aethlon Medical
AEMD
|
-6.97 M | $ 5.53 | 0.73 % | $ 3.73 M | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 2.95 | 0.34 % | $ 121 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 67.19 | -1.94 % | $ 1.99 B |  Costa-rica |
 |
Delcath Systems
DCTH
|
898 K | $ 20.08 | -0.96 % | $ 719 M | USA |
 |
Electromed
ELMD
|
14.7 M | $ 27.2 | 1.29 % | $ 225 M | USA |
 |
Inogen
INGN
|
-9.55 M | $ 6.02 | -1.64 % | $ 160 M | USA |
 |
Globus Medical
GMED
|
757 M | $ 75.35 | -1.34 % | $ 10.2 B | USA |
 |
IRadimed Corporation
IRMD
|
27.3 M | $ 86.87 | -0.08 % | $ 1.11 B | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 8.79 | -4.2 % | $ 249 M | USA |
 |
Accuray Incorporated
ARAY
|
-18.5 M | $ 3.17 | -17.02 % | $ 389 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 50.89 | 0.49 % | $ 2.34 B | USA |
 |
IRIDEX Corporation
IRIX
|
-2.05 M | $ 0.7 | -0.41 % | $ 11.9 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 5.81 | -0.34 % | $ 362 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-449 M | $ 14.54 | 1.18 % | $ 1.11 B | USA |
 |
Bruker Corporation
BRKR
|
288 M | $ 62.25 | -5.4 % | $ 9.45 B | USA |
 |
LivaNova PLC
LIVN
|
228 M | $ 91.39 | -1.32 % | $ 4.99 B |  Britain |
|
LENSAR
LNSR
|
-21 M | $ 4.97 | -8.97 % | $ 59.4 M | USA |
 |
Orthofix Medical
OFIX
|
-4.11 M | $ 7.12 | -9.94 % | $ 282 M |  Curacao |
 |
Pulmonx Corporation
LUNG
|
-52.6 M | $ 2.81 | 0.18 % | $ 114 M | USA |
 |
InspireMD
NSPR
|
426 M | $ 0.78 | 9.49 % | $ 50.2 M | Israel |
 |
InMode Ltd.
INMD
|
86.1 M | $ 13.26 | -1.89 % | $ 857 M | Israel |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 33.43 | -1.65 % | $ 784 M | USA |
 |
Outset Medical
OM
|
-62.4 M | $ 4.22 | 2.43 % | $ 64.2 M | USA |
 |
PAVmed
PAVM
|
-21.7 M | $ 1.64 | 0.31 % | $ 1.1 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.56 | 4.36 % | $ 4.33 M | USA |
 |
AVITA Medical
RCEL
|
-40.2 M | $ 17.62 | 2.92 % | $ 491 M |  Australia |
 |
Tandem Diabetes Care
TNDM
|
26 M | $ 18.7 | 2.92 % | $ 1.27 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 7.72 | 4.97 % | $ 1.04 B | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 62.36 | -3.06 % | $ 1.83 B | USA |
 |
Integer Holdings Corporation
ITGR
|
352 M | $ 126.66 | 0.08 % | $ 4.4 B | USA |
 |
Avanos Medical
AVNS
|
-22.7 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |